Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the ...

On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned ...

In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on Vera Therapeutics (VERA – Research Report), with a price ...

American Century Companies Inc. grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 11.0% ...

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports.

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified ...

April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Vera Therapeutics Inc (Symbol: VERA) entered into oversold territory, hitting an RSI ...

Claim your 7-day free trial now. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in ...

Brisbane, California Saturday, April 5, 2025, 15:00 Hrs [IST] ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...